BioSpace News Archive

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced that Reenie McCarthy, CEO, will present at the virtual Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 3:00 p.m. ET.

OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of its RESPONSE™ Neuromuscular Scoliosis System.

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results with increasing RO over time: receptor saturation at 100 mg BID dose

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including: Jefferies Virtual Healthcare Conference on Tuesday, June 1 st , at 10:00 a.m. ET; William Blair 41 st Annual Growth Stock Conference on Wednesday, June 2 nd , at 11:00 a.m. ET; and

NLS Pharmaceutics Ltd. announces that Alex Zwyer , Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference, which is being held virtually June 1 – June 4, 2021.

Beroni Group, an Australia-based diversified biopharmaceutical enterprise announced that it has raised US$2 million via the issue of convertible notes to an investor in Japan with the following key terms

Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN).

On behalf of the Company, I would like to provide some assurance as to our progress and execution of our business plans.

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test